« Return

Advancing Preclinical Bioanalytical Strategies for Today’s Diverse Vaccine Platforms

As vaccine technologies diversify, so too must the strategies for evaluating their safety and efficacy in the preclinical stage. From traditional attenuated and inactivated vaccines to modern mRNA and viral vector platforms, each vaccine type poses distinct bioanalytical considerations that impact how drug developers approach pharmacokinetics, immunogenicity, and safety assessment.

This blog outlines key preclinical bioanalytical strategies that support the development of a wide range of vaccine modalities, including therapeutic cancer vaccines, helping to ensure regulatory compliance and scientific rigor before entering the clinic.

Understanding Vaccine Mechanisms and Modalities

Classical prophylactic vaccines work by mimicking natural infections to elicit immune responses. Upon administration, they stimulate the innate immune system, which in turn activates adaptive immunity through highly specific T cells and B cells. This dual activation enables the body to produce pathogen-targeting antibodies and memory cells for long-term protection.

Modern vaccines fall into several categories:

Pathogen-based vaccines (e.g., inactivated or live attenuated viruses)
Recombinant vector vaccines (replicating or non-replicating viral vectors)
Protein-based vaccines (subunit vaccines and virus-like particles)
Nucleic acid-based vaccines (DNA and mRNA)

Each category offers unique advantages, such as production scalability or immune specificity, as well as limitations, including immunogenic variability, safety considerations, and delivery challenges.

Therapeutic vaccines represent a newer frontier. These include nucleic acid, cell-based, viral vector, and peptide/protein vaccines that that enhance the immune system’s ability to clear pre-existing pathogens. For example, therapeutic cancer vaccines “train” the immune system to recognize and eliminate cancer cells. While promising, they introduce additional complexity to preclinical evaluation.

Key Objectives in Vaccine Safety Evaluation

Preclinical safety evaluation is essential for identifying potential adverse effects and informing clinical trial design. Safety concerns may result not only from the vaccine components themselves, but also from immune-related mechanisms or residual impurities. Regulatory agencies have issued guidance to support tailored evaluation approaches based on each vaccine’s unique profile.

Typical toxicology assessments include:

Repeat-dose toxicity including local tolerance
Safety pharmacology (case by case basis)
Developmental and reproductive toxicology (as applicable)
Genotoxicity (as applicable)
Immunotoxicity
Biodistribution studies, particularly for nucleic acid and vector-based vaccines

For newer delivery systems such as lipid nanoparticles (LNPs) with novel components or adjuvants, sponsors may need to assess biodistribution and conduct standalone safety studies of these components.

Bioanalytical Approaches: Pharmacokinetics and Biodistribution

While the bioanalysis of traditional vaccines typically doesn’t require pharmacokinetic/toxicokinetic (PK/TK) studies, depending on their characteristics, biodistribution/shedding studies may be performed for some newer vaccine platforms. For example:

mRNA and DNA vaccines: PK studies may use techniques like qPCR or ddPCR to track the presence of genetic material.
Viral vectors: Tissue distribution studies help determine where and how long the vector persists in vivo.
Novel adjuvants: Biodistribution characterization may be required for nucleic acid-based adjuvants.

Understanding the fate of these components in the body is critical to assessing potential off-target risks and supporting safe dose selection.

Assessing Immunogenicity in Preclinical Models

Immunogenicity testing measures a vaccine’s ability to elicit an immune response. Preclinical assessment includes both humoral (antibody-mediated) and cellular responses:

Humoral Immunogenicity: ELISA/ECL is commonly used to quantify antigen-specific antibodies, including IgA for mucosal vaccines. Meanwhile, neutralizing antibodies can be measured by cell-based or non-cell-based methods. If the delivery system (e.g., PEGylated lipids or viral vectors like AAV) is immunogenic, anti-drug antibodies and neutralizing antibodies against the vector must also be assessed.
Cellular Immunogenicity: Assays such as ELISpot, intracellular cytokine staining (ICS), and MHC tetramer analysis provide insight into antigen-specific T-cell activation and effector cell differentiation.

These platforms help developers measure vaccine potency, specificity, and durability of response—critical parameters for candidate selection and clinical development.

Investigating Immunotoxicity Risks

Given the immune-stimulating nature of vaccines, immunotoxicity assessment plays a pivotal role in preclinical research. Evaluations focus on:

Cytokine profiling: Multiplex platforms (e.g., MSD, Luminex, CBA) can detect protective versus toxicity-related cytokines and identify cytokine release syndrome risks.
Immunophenotyping: Flow cytometry-based immunophenotyping reveals shifts in lymphocyte subpopulations and potential immune dysregulation.
Complement and immunoglobulin levels: These biomarkers help detect immune responses as well as adverse effects including hypersensitivity, autoimmunity, and complement-mediated cytotoxicity.

Taken together, these assessments provide a comprehensive view of immune system activation and potential safety concerns.

Building a Comprehensive Vaccine Bioanalysis Platform

At WuXi AppTec, our bioanalytical platforms are built to meet the evolving needs of vaccine developers across modalities. We have validated methods across several different platforms, including:

qPCR and ddPCR: for PK and tissue distribution of nucleic acid vaccines
ELISA and MSD: for biomarker, humoral immunogenicity and anti-drug antibody analysis
ELISpot and CRA: for cellular immune response evaluation
Flow cytometry and Luminex: for immunotoxicity profiling

Our scientists have deep experience supporting preclinical programs under global Good Laboratory Practice (GLP) regulatory frameworks and have developed robust internal methods for multiple species.

Looking Ahead

As vaccine technologies continue to evolve alongside innovations in adjuvants, delivery systems, and therapeutic indications, rigorous preclinical bioanalysis remains foundational to advancing safe and effective candidates. Tailored strategies that align with each vaccine’s mechanism, composition, and risk profile are critical for regulatory success.

WuXi AppTec remains committed to partnering with vaccine developers across the globe, providing scalable and scientifically rigorous solutions to accelerate the path from discovery to clinical impact.

Learn more about WuXi AppTec’s bioanalytical services or talk to an expert today.

A New Playbook: 5 Ways to Improve Safety & Decision-Making With In Vitro Toxicology

In vitro toxicology is quickly becoming the most effective way to upgrade drug development and safety programs while staying compliant with evolving regulations. What used to be viewed as “nice-to-have” early screens are now widely used to deliver faster, more human-relevant insight into potential risk, while also reducing reliance on in vivo models. Regulatory bodies worldwide have also urged a shift away from animal studies, prompting drug developers to find new ways to make smarter early decisions, protect timelines, and build clearer, more persuasive safety narratives around their compounds. Here are five ways to align your drug development program with the rapidly evolving expectations of in vitro toxicology.

IND-Ready Immunotoxicity: Four Decisions to Prevent Late Surprises

Immune-modulating therapies, like bispecific T cell engagers (TCEs) and mRNA vaccines can be incredibly effective, but they can also trigger fast, hard-to-predict immune side effects that are costly if uncovered late in the development process. The question every team preparing for Investigational New Drug (IND) applications and first-in-human (FIH) decisions should be asking themselves is simple: How do we create an immunotoxicity strategy that is appropriate for IND submission and still executable on a real timeline?